Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
176 hedge funds and large institutions have $1.63B invested in Intra-Cellular Therapies Inc. in 2020 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 71 increasing their positions, 39 reducing their positions, and 20 closing their positions.
135% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 20
82% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 39
31% more capital invested
Capital invested by funds: $1.25B → $1.63B (+$383M)
23% more call options, than puts
Call options by funds: $38.2M | Put options by funds: $31M
18% more funds holding
Funds holding: 149 → 176 (+27)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$75.5M |
| 2 |
Millennium Management
New York
|
+$41.3M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$39.9M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$38.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SLT
St Louis Trust
Saint Louis,
Missouri
|
-$22.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.8M |
| 3 |
Goldman Sachs
New York
|
-$10.1M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$6.08M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$4.56M |
ITCI Hedge Fund Activity: Q3 2020 in Review
176 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2020, worth a combined $1.63B — up 31% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new ITCI positions and 20 closed out — a net gain of 27 holders — while 71 added to existing stakes and 39 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $75.5M. The largest seller was St Louis Trust, exiting entirely with an estimated $22.6M sold.
- 176 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2020, up from 149 in Q2 2020.
- Funds reported $1.63B of Intra-Cellular Therapies Inc. stock for Q3 2020, up 31% quarter-over-quarter.
- 47 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2020 and 20 closed out, a net change of +27 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q3 2020 was Fidelity Investments, an estimated $75.5M added.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2020 was St Louis Trust, an estimated $22.6M sold.
Based on aggregated 13F filings for Q3 2020.